<i><scp>RAS</scp></i> and <i><scp>BRAF</scp></i> mutations in cell‐free <scp>DNA</scp> are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested <i><scp>RAS</scp></i> wild‐type advanced colorectal cancer
Molecular oncology